- Home
- CTLT
CTLT
Catalent Inc.
as 10-17-2024 4:00pm EST
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SOMERSET |
| Market Cap: | 11.0B | IPO Year: | 2014 |
| Target Price: | $59.83 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $31.80 - $61.20 | Next Earning Date: | 11-13-2024 |
| Revenue: | $4,381,000,000 | Revenue Growth: | 2.77% |
| Revenue Growth (this year): | 9.43% | Revenue Growth (next year): | 8.24% |
Stock Insider Trading Activity of Catalent Inc. (CTLT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McErlane David | CTLT | Group President, Biologics | Sep 26 '24 | Sell | $59.97 | 1,994 | $119,580.18 | 36,304 | |
| Gunther Scott | CTLT | SVP, Quality & Reg. Affairs | Aug 2 '24 | Sell | $59.55 | 666 | $39,660.30 | 39,635 | |
| Hopson Ricky | CTLT | Pres. BioProduct Delivery, CoS | Aug 2 '24 | Sell | $59.56 | 662 | $39,428.72 | 29,974 | |
| Gennadios Aristippos | CTLT | Group Pres. Pharma & Consumer | Aug 2 '24 | Sell | $59.55 | 1,169 | $69,613.95 | 113,724 | |
| Evoli Lisa | CTLT | SVP, Chief HR Officer | Aug 2 '24 | Sell | $59.67 | 3,859 | $230,266.53 | 39,366 | |
| Hopson Ricky | CTLT | Pres. BioProduct Delivery, CoS | Jul 26 '24 | Sell | $58.67 | 206 | $12,086.02 | 29,974 | |
| Gennadios Aristippos | CTLT | Group Pres. Pharma & Consumer | Jul 26 '24 | Sell | $58.70 | 349 | $20,486.30 | 113,724 | |
| Maselli Alessandro | CTLT | President & CEO | Jul 26 '24 | Sell | $58.76 | 9,088 | $534,010.88 | 177,521 |
Latest Catalent Inc. News
CTLT Breaking Stock News: Dive into CTLT Ticker-Specific Updates for Smart Investing
Reuters
9 hours ago
Consumer groups ask FTC to block Novo Holdings-Catalent deal
Zacks
a day ago
Catalent Stock Flat Following the Sell Agreement With Ardena
MT Newswires
4 days ago
Catalent to Sell Oral Solids Facility in New Jersey to Ardena
Reuters
4 days ago
Catalent to sell New Jersey facility
Business Wire
4 days ago
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
MT Newswires
7 days ago
Update: Senator Warren Asks US Antitrust Regulator to 'Carefully Scrutinize' Novo Nordisk's Bid for Catalent
MT Newswires
7 days ago
Update: Senator Warren Asks US Antitrust Regulator to 'Carefully Scrutinize' Novo Nordisk's Bid for Catalent
MT Newswires
8 days ago
Senator Warren Asks US Antitrust Regulator to 'Carefully Scrutinize' Novo Nordisk's Bid for Catalent
Compare CTLT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTLT Catalent Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.